Palisade Bio, Inc.
PALIPalisade Bio is a clinical-stage biopharmaceutical company focused on developing next-generation, oral prodrugs for the treatment of inflammatory and fibrotic diseases.
Table of contents
Earnings
Next report
Aug 10, 2026 (In 1 week)Competitors
By market cap
Profile
Palisade Bio is a clinical-stage biopharmaceutical company focused on developing next-generation, oral prodrugs for the treatment of inflammatory and fibrotic diseases. The company's core value proposition lies in its targeted delivery technology, which bioactivates drugs locally in the lower intestine to improve therapeutic efficacy while minimizing systemic toxicity and side effects. Its lead programs utilize a precision medicine approach, incorporating biomarker-based patient selection to identify individuals most likely to respond to therapy.
Palisade Bio is a clinical-stage developer of first-in-class targeted PDE4 inhibitors, differentiating itself through a localized bioactivation strategy and a biomarker-driven precision medicine platform.
Questions, answered.
- What is Palisade Bio, Inc.'s market cap?
- Palisade Bio, Inc. (PALI) has a market capitalization of $352.8M and trades on NASDAQ.
- Who are Palisade Bio, Inc.'s competitors?
- Palisade Bio, Inc.'s key competitors include Merck, Spyre Therapeutics, Contineum Therapeutics, Inc. Class A Common Stock, and others. These companies compete in similar markets and product categories.
- Who does Palisade Bio, Inc. partner with?
- Palisade Bio, Inc.'s notable partners include Giiant Pharma, Inc., Newsoara, The Regents of the University of California, and others.
- What subsidiaries does Palisade Bio, Inc. have?
- Palisade Bio, Inc.'s subsidiaries include Leading BioSciences, Inc. (LBS), Suzhou Neuralstem Biopharmaceutical Co., Ltd..
- Where is Palisade Bio, Inc. headquartered?
- Palisade Bio, Inc. is headquartered in United States of America and employs approximately 9 people. It has been publicly traded since 2021.